Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine for irritable bowel syndrome
2007-003280-41Phase 3Active
- Sponsor
- SOFAR
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Salcrozine in irritable bowel syndrome (IBS) (2 arms), sponsored by SOFAR. Primary endpoint: Satisfactory relief of abdominal discomfort or pain. Started Nov 2007; status: active.
02
Drugs
Salcrozine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2007-003280-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003280-41.